These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25368431)

  • 1. The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.
    Luo LY; Kim E; Cheung HW; Weir BA; Dunn GP; Shen RR; Hahn WC
    Mol Cancer Res; 2015 Mar; 13(3):502-9. PubMed ID: 25368431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
    Zhang K; Chu K; Wu X; Gao H; Wang J; Yuan YC; Loera S; Ho K; Wang Y; Chow W; Un F; Chu P; Yen Y
    Cancer Res; 2013 Feb; 73(4):1298-307. PubMed ID: 23393200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.
    Dunn GP; Cheung HW; Agarwalla PK; Thomas S; Zektser Y; Karst AM; Boehm JS; Weir BA; Berlin AM; Zou L; Getz G; Liu JF; Hirsch M; Vazquez F; Root DE; Beroukhim R; Drapkin R; Hahn WC
    Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1102-7. PubMed ID: 24385586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
    Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
    EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
    Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
    Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
    BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer.
    Nakamura K; Reid BM; Chen A; Chen Z; Goode EL; Permuth JB; Teer JK; Tyrer J; Yu X; Kanetsky PA; Pharoah PD; Gayther SA; Sellers TA; Lawrenson K; Karreth FA
    Am J Hum Genet; 2022 Jan; 109(1):116-135. PubMed ID: 34965383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.
    Hanes R; Munthe E; Grad I; Han J; Karlsen I; McCormack E; Meza-Zepeda LA; Stratford EW; Myklebost O
    Cells; 2019 Feb; 8(2):. PubMed ID: 30795553
    [No Abstract]   [Full Text] [Related]  

  • 10. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
    Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
    Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.
    Amoroso L; Ognibene M; Morini M; Conte M; Di Cataldo A; Tondo A; D'Angelo P; Castellano A; Garaventa A; Lasorsa VA; Podestà M; Capasso M; Pezzolo A
    Genes Chromosomes Cancer; 2020 May; 59(5):277-285. PubMed ID: 31756773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
    Davis SJ; Sheppard KE; Anglesio MS; George J; Traficante N; Fereday S; Intermaggio MP; Menon U; Gentry-Maharaj A; Lubinski J; Gronwald J; Pearce CL; Pike MC; Wu A; Kommoss S; Pfisterer J; du Bois A; Hilpert F; Ramus SJ; Bowtell DD; Huntsman DG; Pearson RB; Simpson KJ; Campbell IG; Gorringe KL
    Mol Cancer Ther; 2015 Jun; 14(6):1495-503. PubMed ID: 25852062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.
    Wang X; Asmann YW; Erickson-Johnson MR; Oliveira JL; Zhang H; Moura RD; Lazar AJ; Lev D; Bill K; Lloyd RV; Yaszemski MJ; Maran A; Oliveira AM
    Genes Chromosomes Cancer; 2011 Nov; 50(11):849-58. PubMed ID: 21793095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplicon profiles in ovarian serous carcinomas.
    Nakayama K; Nakayama N; Jinawath N; Salani R; Kurman RJ; Shih IeM; Wang TL
    Int J Cancer; 2007 Jun; 120(12):2613-7. PubMed ID: 17351921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BBOX1 mediates metabolic reprogramming driven by hypoxia and participates in the malignant progress of high-grade serous ovarian cancer.
    Huang J; Tang Y; Li Y; Wei W; Kang F; Tan S; Lin L; Lu X; Wei H; Wang N
    Biochim Biophys Acta Mol Cell Res; 2024 Dec; 1871(8):119830. PubMed ID: 39181218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; ; Bowtell D; Waring P
    Gynecol Oncol; 2018 Nov; 151(2):327-336. PubMed ID: 30209015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma.
    Shih IeM; Nakayama K; Wu G; Nakayama N; Zhang J; Wang TL
    Mod Pathol; 2011 May; 24(5):638-45. PubMed ID: 21240255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.
    Liu Z; Gersbach E; Zhang X; Xu X; Dong R; Lee P; Liu J; Kong B; Shao C; Wei JJ
    Mol Cancer Res; 2013 Nov; 11(11):1314-25. PubMed ID: 24045973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
    Bungsy M; Palmer MCL; Jeusset LM; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
    Cancer Lett; 2021 Mar; 500():194-207. PubMed ID: 33290867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
    Rhyasen GW; Yao Y; Zhang J; Dulak A; Castriotta L; Jacques K; Zhao W; Gharahdaghi F; Hattersley MM; Lyne PD; Clark E; Zinda M; Fawell SE; Mills GB; Chen H
    PLoS One; 2018; 13(7):e0200826. PubMed ID: 30036377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.